A Two-Week Study of the Efficacy and Safety of Mifepristone in the Prevention of Olanzapine-Induced Weight Gain
This study has been completed.
Eli Lilly and Company
Information provided by:
First received: March 30, 2007
Last updated: September 18, 2008
Last verified: September 2008
This is a two-week study testing the efficacy and safety of mifepristone in the prevention of olanzapine-induced weight gain in healthy male volunteers by measuring changes in body weight and BMI.
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
|Official Title:||A Two-Week, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone in the Prevention of Olanzapine-Induced Weight Gain in Healthy Male Volunteers|
Resource links provided by NLM:
Further study details as provided by Corcept Therapeutics:
Primary Outcome Measures:
- To determine the efficacy of mifepristone in the prevention of olanzapine-induced weight gain in healthy male volunteers.
Secondary Outcome Measures:
- To determine the tolerability and safety of the administration of mifepristone and olanzapine in healthy male volunteers.
|Study Start Date:||March 2007|
|Study Completion Date:||July 2007|
Contacts and Locations